Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice

Molecular Immunology

Volumn 56, Issue 4, 2013, Pages 649-659

  Karakhanova, Svetlana ^a   Yang, Yuhui ^a,b   Link, Julia ^a   Soltek, Sabine ^a   von Ahn, Katharina ^a   Umansky, Viktor ^c,d   Werner, Jens ^a   Bazhin, Alexandr V ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CGMP; Gender specific effects; Immune cells; Immunomodulation; Phosphodiesterase 5; Sildenafil

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLIC GMP; INTERLEUKIN 6; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; CD11B ANTIGEN; CHEMOKINE RECEPTOR; GR-1 PROTEIN, MOUSE; PHOSPHODIESTERASE V; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; EX VIVO STUDY; IMMUNE SYSTEM; IMMUNOLOGY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; SPLEEN CELL; ANIMAL; B LYMPHOCYTE; BLOOD; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD11B; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INTERLEUKIN-6; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; MYELOID CELLS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX FACTORS; SPLEEN; SULFONES; T-LYMPHOCYTES;

EID: 84881114389     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.06.021     Document Type: Article

References (34)

1. Bazhin A.V., Schadendorf D., Owen R.W., Zernii E.Y., Philippov P.P., Eichmüller S.B. Visible light modulates the expression of cancer-retina antigens. Molecular Cancer Research 2008, 6(1):110-118.
2. Boswell-Smith V., Spina D., Page C.P. Phosphodiesterase inhibitors. British Journal of Pharmacology 2006, 147(Suppl. 1):S252-S257.
3. Corbin J.D., Francis S.H., Webb D.J. Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. Urology 2002, 60(2 (Suppl. 2)):4-11.
4. D'Agostino P., Milano S., Barbera C., Di Bella G., La Rosa M., Ferlazzo V., Farruggio R., Miceli D.M., Miele M., Castagnetta L., Cillari E. Sex hormones modulate inflammatory mediators produced by macrophages. Annals of the New York Academy of Sciences 1999, 876:426-429.
5. Escribese M.M., Kraus T., Rhee E., Fernandez-Sesma A., Lopez C.B., Moran T.M. Estrogen inhibits dendritic cell maturation to RNA viruses. Blood 2008, 112(12):4574-4584.
6. Fish E.N. The X-files in immunity: sex-based differences predispose immune responses. Nature Reviews 2008, 8(9):737-744.
7. Francis S.H., Busch J.L., Corbin J.D., Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacological Reviews 2010, 62(3):525-563.
8. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews 2009, 9(3):162-174.
9. Hou J., Zheng W.F. Effect of sex hormones on NK and ADCC activity of mice. International Journal of Immunopharmacology 1988, 10(1):15-22.
10. Hunt C.M., Westerkam W.R., Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology 1992, 44(2):275-283.
11. Hyland R., Roe E.G., Jones B.C., Smith D.A. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology 2001, 51(3):239-248.
12. Jimenez-Caliani A.J., Jimenez-Jorge S., Molinero P., Fernandez-Santos J.M., Martin-Lacave I., Rubio A., Guerrero J.M., Osuna C. Sex-dependent effect of melatonin on systemic erythematosus lupus developed in Mrl/Mpj-Faslpr mice: it ameliorates the disease course in females, whereas it exacerbates it in males. Endocrinology 2006, 147(4):1717-1724.
13. Klein S.L. Immune cells have sex and so should journal articles. Endocrinology 2012, 153(6):2544-2550.
14. Libert C., Dejager L., Pinheiro I. The X chromosome in immune functions: when a chromosome makes the difference. Nature Reviews 2010, 10(8):594-604.
15. Lin P.Y., Sun L., Thibodeaux S.R., Ludwig S.M., Vadlamudi R.K., Hurez V.J., Bahar R., Kious M.J., Livi C.B., Wall S.R., Chen L., Zhang B., Shin T., Curiel T.J. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. Journal of Immunology 2010, 185(5):2747-2753.
16. Meyer C., Sevko A., Ramacher M., Bazhin A.V., Falk C.S., Osen W., Borrello I., Kato M., Schadendorf D., Baniyash M., Umansky V. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(41):17111-17116.
17. Omori K., Kotera J. Overview of PDEs and their regulation. Circulation Research 2007, 100(3):309-327.
18. Paharkova-Vatchkova V., Maldonado R., Kovats S. Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors. Journal of Immunology 2004, 172(3):1426-1436.
19. Raja S.G. Cardioprotection with sildenafil: implications for clinical practice. Current Medicinal Chemistry 2006, 13(26):3155-3164.
20. Rettew J.A., Huet-Hudson Y.M., Marriott I. Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity. Biology of Reproduction 2008, 78(3):432-437.
21. Sanchez Luna M., Franco M.L., Bernardo B. Therapeutic strategies in pulmonary hypertension of the newborn: where are we now?. Current Medicinal Chemistry 2012, 19(27):4640-4653.
22. Sarfati M., Mateo V., Baudet S., Rubio M., Fernandez C., Davi F., Binet J.L., Delic J., Merle-Beral H. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003, 101(1):265-269.
23. Scandlyn M.J., Stuart E.C., Rosengren R.J. Sex-specific differences in CYP450 isoforms in humans. Expert Opinion on Drug Metabolism & Toxicology 2008, 4(4):413-424.
24. Schmidt C.J. Phosphodiesterase inhibitors as potential cognition enhancing agents. Current Topics in Medicinal Chemistry 2010, 10(2):222-230.
25. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 2008, 3(6):1101-1108.
26. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. Journal of Experimental Medicine 2006, 203(12):2691-2702.
27. Shevchenko I., Karakhanova S., Soltek S., Link J., Bayry J., Werner J., Umansky V., Bazhin A.V. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. International Journal of Cancer 2012, 133:98-107.
28. Sutherland E.W., Rall T.W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. Journal of Biological Chemistry 1958, 232(2):1077-1091.
29. Szczypka M., Obminska-Mrukowicz B. The effects of selective and nonselective phosphodiesterase inhibitors on phagocytic cells in mice. Immunopharmacology and Immunotoxicology 2010, 32(3):507-513.
30. Szczypka M., Obminska-Mrukowicz B. Modulating effects of nonselective and selective phosphodiesterase inhibitors on lymphocyte subsets and humoral immune response in mice. Pharmacological Reports 2010, 62(6):1148-1158.
31. Ueno K., Sato H. Sex-related differences in pharmacokinetics and pharmacodynamics of anti-hypertensive drugs. Hypertension Research 2012, 35(3):245-250.
32. Waxman D.J., Holloway M.G. Sex differences in the expression of hepatic drug metabolizing enzymes. Molecular Pharmacology 2009, 76(2):215-228.
33. Yang Y., Karakhanova S., Soltek S., Werner J., Philippov P.P., Bazhin A.V. In vivo immunoregulatory properties of the novel mitochondria-targeted antioxidant SkQ1. Molecular Immunology 2012, 52(1):19-29.
34. Zhang L., Zhang R.L., Wang Y., Zhang C., Zhang Z.G., Meng H., Chopp M. Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36(4):847-852.